Cargando…

A Prospective Longitudinal Study of the Effects of Eslicarbazepine Acetate Treatment on Bone Density and Metabolism in Patients with Focal-Onset Epilepsy

BACKGROUND AND OBJECTIVES: Eslicarbazepine acetate (ESL) is a third-generation anti-seizure medication for patients with focal-onset epilepsy. There are known short-term impacts of classic enzyme-inducing drugs on bone health. For oxcarbazepine, which like ESL is a less potent inducer of cytochrome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirsch, Martin, Immisch, Ilka, Knake, Susanne, Schulze-Bonhage, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667382/ https://www.ncbi.nlm.nih.gov/pubmed/37921919 http://dx.doi.org/10.1007/s40263-023-01045-0

Ejemplares similares

Eslicarbazepine Acetate Modulates EEG Activity and Connectivity in Focal Epilepsy
por: Pellegrino, Giovanni, et al.
Publicado: (2018)

Adjunctive Treatment With Eslicarbazepine Acetate for Adults and Children With Focal-Onset Epilepsy: A Meta-Analysis
por: Fei, Yanqing, et al.
Publicado: (2022)

Update on the role of eslicarbazepine acetate in the treatment of partial-onset epilepsy
por: Tambucci, Renato, et al.
Publicado: (2016)

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action
por: Soares-da-Silva, Patrício, et al.
Publicado: (2015)

Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy
por: Saxena, S., et al.
Publicado: (2021)

A Review of Eslicarbazepine Acetate for the Adjunctive Treatment of Partial-Onset Epilepsy
por: Singh, Rajinder P., et al.
Publicado: (2011)

Dibenzazepine Agents in Epilepsy: How Does Eslicarbazepine Acetate Differ?
por: Lawthom, Charlotte, et al.
Publicado: (2018)

Update on treatment of partial onset epilepsy: role of eslicarbazepine
por: Rauchenzauner, Markus, et al.
Publicado: (2010)

Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy
por: Lattanzi, Simona, et al.
Publicado: (2018)

Long‐term efficacy and safety of eslicarbazepine acetate monotherapy for adults with newly diagnosed focal epilepsy: An open‐label extension study
por: Trinka, Eugen, et al.
Publicado: (2020)

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
por: Altalib, Hamada, et al.
Publicado: (2022)

Role of eslicarbazepine in the treatment of epilepsy in adult patients with partial-onset seizures
por: Brown, Martin E, et al.
Publicado: (2010)

Eslicarbazepine acetate in post‐stroke epilepsy: Clinical practice evidence from Euro‐Esli
por: Sales, Francisco, et al.
Publicado: (2020)

Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy
por: Sunkaraneni, Soujanya, et al.
Publicado: (2017)

Comments on the Eslicarbazepine Acetate Section of the Article ‘Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications’
por: Öztiryaki, Ahmet H., et al.
Publicado: (2010)

Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures
por: Costa, Raquel, et al.
Publicado: (2018)

Safety and Tolerability of Adjunctive Eslicarbazepine Acetate in Pediatric Patients (Aged 4-17 Years) With Focal Seizures
por: Mintz, Mark, et al.
Publicado: (2019)

Antiepileptogenesis after stroke—trials and tribulations: Methodological challenges and recruitment results of a Phase II study with eslicarbazepine acetate
por: Koepp, Matthias J., et al.
Publicado: (2023)

Affective Empathy, Theory of Mind and Social Functioning in Patients With Focal Epilepsy
por: Metternich, Birgitta, et al.
Publicado: (2022)

Focal Cortex Stimulation With a Novel Implantable Device and Antiseizure Outcomes in 2 Prospective Multicenter Single-Arm Trials
por: Schulze-Bonhage, Andreas, et al.
Publicado: (2023)

Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience
por: Gama, Helena, et al.
Publicado: (2017)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Eslicarbazepine acetate as adjunctive therapy in clinical practice: ESLADOBA study
por: Chaves, J., et al.
Publicado: (2017)

Serum sodium levels and related treatment‐emergent adverse events during eslicarbazepine acetate use in adults with epilepsy
por: Wechsler, Robert T., et al.
Publicado: (2019)

Eslicarbazepine Acetate: A New Improvement on a Classic Drug Family for the Treatment of Partial-Onset Seizures
por: Galiana, Graciana L., et al.
Publicado: (2017)

Modeling and simulations to support dose selection for eslicarbazepine acetate therapy in pediatric patients with partial-onset seizures
por: Sunkaraneni, Soujanya, et al.
Publicado: (2018)

Brivaracetam in the Treatment of Patients with Epilepsy—First Clinical Experiences
por: Zahnert, Felix, et al.
Publicado: (2018)

Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses
por: Mehta, Darshan, et al.
Publicado: (2020)

Comparative Economic Outcomes in Patients with Focal Seizure Initiating First-Line Eslicarbazepine Acetate Monotherapy versus Generic Antiseizure Drugs
por: Mehta, Darshan, et al.
Publicado: (2021)

Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate
por: Gidal, B. E., et al.
Publicado: (2018)

Transition from oxcarbazepine to eslicarbazepine acetate: A single center study
por: Mäkinen, Jussi, et al.
Publicado: (2017)

Intra- and Inter-Subject Perspectives on the Detection of Focal Onset Motor Seizures in Epilepsy Patients
por: Böttcher, Sebastian, et al.
Publicado: (2022)

New and Emerging Treatments for Epilepsy: Review of Clinical Studies of Lacosamide, Eslicarbazepine Acetate, Ezogabine, Rufinamide, Perampanel, and Electrical Stimulation Therapy
por: Chung, Steve S., et al.
Publicado: (2011)

Termination of seizures by ictal transcranial focal cortex stimulation
por: Hirsch, Martin, et al.
Publicado: (2023)

Brivaracetam substituting other antiepileptic treatments: Results of a retrospective study in German epilepsy centers
por: Lerche, Holger, et al.
Publicado: (2020)

Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures
por: Villanueva, Vicente, et al.
Publicado: (2017)

Eslicarbazepine acetate: its effectiveness as adjunctive therapy in clinical trials and open studies
por: Shorvon, S. D., et al.
Publicado: (2017)

Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Na(v)1.5 Channels
por: Leslie, Theresa K., et al.
Publicado: (2020)

Eslicarbazepine acetate is porphyrogenic and should be used with caution in patients with the acute hepatic porphyrias
por: Ma, Christopher D., et al.
Publicado: (2022)

Pooled efficacy and safety of eslicarbazepine acetate as add‐on treatment in patients with focal‐onset seizures: Data from four double‐blind placebo‐controlled pivotal phase III clinical studies
por: Elger, Christian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_gs2irerqff47lcmc6nramcl74a